Related Experiment Video

Updated: Sep 23, 2026

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms
06:50

A Soluble Tetrazolium-Based Reduction Assay to Evaluate the Effect of Antibodies on Candida tropicalis Biofilms

Published on: September 16, 2022

New strategies for treatment of Candida vaginal infections

Walter Magliani1, Stefania Conti, Antonella Salati

  • 1Dipartimento di Patologia e Medicina di Laboratorio, Sezione di Microbiologia, Universita degli Studi di Parma, Viale Gramsci 14, 43100 Parma, Italy. magliwal@unipr.it

Revista Iberoamericana De Micologia
|June 27, 2003
PubMed

Insights

New treatments for vaginal candidiasis are emerging. Killer antibodies and specific receptors offer potential therapeutic and preventative strategies against this common fungal infection.

Area of Science:

  • Mycology
  • Immunology
  • Pharmacology

Background:

  • Vaginal candidiasis is a widespread infection, often recurrent.
  • Existing antifungal treatments have limitations in safety and efficacy.
  • Preventative strategies for vaginal candidiasis are lacking.

Purpose of the Study:

  • To review novel chemotherapeutic and immunotherapeutic strategies for vaginal candidiasis.
  • To discuss new approaches based on understanding the infection's immunopathogenesis.
  • To highlight potential therapeutic and preventative agents.

Main Methods:

  • Review of recent literature on vaginal candidiasis treatment.
  • Analysis of immunopathogenesis to identify therapeutic targets.
  • Focus on killer antibodies and yeast killer toxin (KT) receptors.

Main Results:

  • Killer antibodies, with internal images of yeast killer toxin (KT), show broad microbicidal activity.
  • Specific cell wall KT receptors are identified as potential targets.
  • These agents offer promise for both treatment and prevention.

Conclusions:

  • Novel therapeutic strategies for vaginal candidiasis are being developed.
  • Killer antibodies and KT receptor-based approaches show significant potential.
  • These new strategies may address limitations of current antifungal treatments and prevention.

More Related Videos

Protocols for Vaginal Inoculation and Sample Collection in the Experimental Mouse Model of Candida vaginitis07:57

Protocols for Vaginal Inoculation and Sample Collection in the Experimental Mouse Model of Candida vaginitis

Published on: December 8, 2011

Curcuminoid-Mediated Antimicrobial Photodynamic Therapy on a Murine Model of Oral Candidiasis06:39

Curcuminoid-Mediated Antimicrobial Photodynamic Therapy on a Murine Model of Oral Candidiasis

Published on: October 27, 2023

Related Concept Videos

Candidiasis01:20

Candidiasis

Candidiasis is a fungal infection caused by opportunistic species of Candida. It can affect various anatomical sites, including the skin, oral cavity, nails, and genitourinary tract. Among its forms, vaginal candidiasis is the most common type of mucosal infection. It typically results from the overgrowth of Candida albicans in the vaginal mucosa. Under normal conditions, C. albicans exists as a commensal organism within the vaginal microbiota, regulated by the dominance of lactobacilli, which...
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to cholesterol contributes to...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Trichomoniasis01:18

Trichomoniasis

Trichomonas vaginalis is a flagellated protozoan parasite and the causative agent of trichomoniasis, one of the most prevalent non-viral sexually transmitted infections in the United States. This extracellular parasite primarily colonizes the lower genitourinary tract in women—particularly the vagina—and in men, the urethra and prostate. Its structural and functional adaptations enable its survival, motility, and pathogenicity within the host environment.Structural Features and Host EntryT.
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...